Reveal the chemistry behind the MRI images you already acquire.
Magnetic Resonance Spectroscopy can aid in diagnosing and monitoring brain tumors by analyzing their chemical composition, distinguishing tumor types, tracking treatment progress, and detecting potential recurrence.
From initial tumor characterization to longitudinal treatment monitoring, Magnetic Resonance Spectroscopy provides non-invasive metabolic intelligence across the full neuro-oncology care continuum.
Quantify 2-hydroxyglutarate (2-HG) to non-invasively identify IDH-mutant gliomas with 95% sensitivity and 91% specificity, providing critical information about tissue composition without requiring a traditional surgical biopsy.
Differentiate high-grade from low-grade gliomas using metabolic ratios such as Cho/NAA and Cho/Cr. Elevated choline and reduced NAA correlate with increased cellularity and neuronal loss.
Differentiate treatment-related radiation necrosis and pseudoprogression from true tumor recurrence. Both appear similar on conventional MRI, but MRS reveals distinct metabolic profiles.
Monitor metabolic response over time by tracking quantitative biomarkers across serial MRS scans, enabling earlier, data-driven decisions about continuing, adjusting, or changing therapy.
Characterize cystic brain lesions non-invasively by analyzing their metabolic composition. MRS can distinguish neoplastic cysts from abscesses, arachnoid cysts, and other fluid-filled lesions.
Spectroscopy provides actionable metabolic intelligence to every stakeholder.